All patients
Age < 65y (younger) Age > 65y Asian type cancer location (gastric) cancer location (gastro-esophageal) Gender, female Gender, male PDL1 (CPS >1) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) previous gastrectomy previous gastrectomy NO
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
mGC or mGEJC - M - HER2 negative, immune chekpoint inhibitors vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results JAVELIN Gastric 100, 2020 0.91 [0.74; 1.11]
0.91 [0.74 ; 1.11 ] JAVELIN Gastric 100, 2020 1 0% 499 NA not evaluable progression or deaths (PFS)detailed results JAVELIN Gastric 100, 2020 1.04 [0.85; 1.28]
1.04 [0.85 ; 1.28 ] JAVELIN Gastric 100, 2020 1 0% 499 NA not evaluable DCRdetailed results JAVELIN Gastric 100, 2020 0.62 [0.43; 0.89]
0.62 [0.43 ; 0.89 ] JAVELIN Gastric 100, 2020 1 0% 499 NA not evaluable objective responses (ORR)detailed results JAVELIN Gastric 100, 2020 0.91 [0.55; 1.51]
0.91 [0.55 ; 1.51 ] JAVELIN Gastric 100, 2020 1 0% 499 NA not evaluable AE (any grade)detailed results JAVELIN Gastric 100, 2020 1.25 [0.67; 2.33]
1.25 [0.67 ; 2.33 ] JAVELIN Gastric 100, 2020 1 0% 481 NA not evaluable AE (grade 3-4)detailed results JAVELIN Gastric 100, 2020 0.98 [0.68; 1.40]
0.98 [0.68 ; 1.40 ] JAVELIN Gastric 100, 2020 1 0% 481 NA not evaluable AE leading to death (grade 5)detailed results JAVELIN Gastric 100, 2020 1.22 [0.57; 2.59]
1.22 [0.57 ; 2.59 ] JAVELIN Gastric 100, 2020 1 0% 481 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results JAVELIN Gastric 100, 2020 0.43 [0.28; 0.64]
0.43 [0.28 ; 0.64 ] JAVELIN Gastric 100, 2020 1 0% 481 NA not evaluable SAE (any grade)detailed results JAVELIN Gastric 100, 2020 1.26 [0.86; 1.83]
1.26 [0.86 ; 1.83 ] JAVELIN Gastric 100, 2020 1 0% 481 NA not evaluable STRAE (any grade)detailed results JAVELIN Gastric 100, 2020 0.79 [0.42; 1.50]
0.79 [0.42 ; 1.50 ] JAVELIN Gastric 100, 2020 1 0% 481 NA not evaluable TRAE (any grade)detailed results JAVELIN Gastric 100, 2020 0.47 [0.31; 0.69]
0.47 [0.31 ; 0.69 ] JAVELIN Gastric 100, 2020 1 0% 481 NA not evaluable TRAE (grade 3-4)detailed results JAVELIN Gastric 100, 2020 0.31 [0.19; 0.49]
0.31 [0.19 ; 0.49 ] JAVELIN Gastric 100, 2020 1 0% 481 NA not evaluable TRAE leading to death (grade 5)detailed results JAVELIN Gastric 100, 2020 0.49 [0.02; 14.64]
0.49 [0.02 ; 14.64 ] JAVELIN Gastric 100, 2020 1 0% 481 NA not evaluable TRAE leading to discontinuation (any grade)detailed results JAVELIN Gastric 100, 2020 0.31 [0.18; 0.50]
0.31 [0.18 ; 0.50 ] JAVELIN Gastric 100, 2020 1 0% 481 NA not evaluable 0.2 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-10 22:44 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 186
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,746,745,856,634,861,416,864,769,980,369,743
